SLC27A5 and hepatocellular carcinoma: Additionally, experimental animal models in vivo confirmed that the loss of FATP5 promotes HCC tumorigenesis and metastasis via the AMPK pathway, while activating AMPK by metformin reversed these effects and dramatically suppressed tumor progression.